False Statements

Erasca Faces Securities Suit Over ERAS-0015 After Patent Claim and Trial Death Disclosures

Investors say April disclosures of a Revolution Medicines patent letter and a Phase 1 patient death undercut Erasca’s prior preclinical claims and triggered a fight for lead-plaintiff control.